AI Develops a New Vaccine Type to Combat Multiple Viruses
Researchers have utilized artificial intelligence to create a "fundamentally new" vaccine capable of protecting against a broad range of viruses and potentially preventing future pandemics.
The team at the University of Cambridge reports this as the first instance where a vaccine's key component has been entirely designed by AI and subsequently tested in humans.
The vaccine was engineered to target all coronaviruses, encompassing all Covid variants and viruses that infect animals but could trigger the next pandemic.
The research remains in early stages, yet the team is advancing separate vaccines aimed at influenza and Ebola.
Vaccines function by teaching the immune system to recognize infections, enhancing the body's ability to combat them.
However, some viruses frequently mutate, altering their appearance and rendering vaccines quickly outdated. This necessitates regular updates for Covid and seasonal flu vaccines.
"We're always behind," said Prof Jonathan Heeney, from the University of Cambridge, adding"what we're trying to do is get ahead of the curve" and so far ahead they could protect against new outbreaks or pandemics.
How Does the AI-Designed Vaccine Work?
Traditionally, vaccines are developed using a current virus strain.
Cambridge researchers collected known genetic codes—the instruction manuals of life—from various coronaviruses identified by surveillance programs monitoring potential viral threats.
These genetic sequences were analyzed by artificial intelligence, which then designed a "super-antigen" capable of training the immune system to provide protection across the entire virus family, even if mutations occur or a new infection transfers from animals to humans.
Antigens are the critical vaccine components that the immune system learns to target.
Heeney emphasized this as the first time an AI-designed antigen has been trialed in humans, describing the technology as "surprising all of us" and "amazing what we can do with it for the good of humanity."
Heeney told : "This is about making vaccines that protect us, not just from today's viruses, but protect us from what can cause the next outbreak or disease.
This is a fundamental shift in how we prepare for pandemics."
The initial trials involved 39 participants and aimed to assess vaccine safety. A subsequent study with approximately 200 participants will evaluate the vaccine's effectiveness in training the immune system.
The findings, published in the Journal of Infection, indicated the immune response was "modest," yet the results have generated considerable excitement.
Prof Saul Faust, who conducted some trials at the University of Southampton, stated the AI design "definitely has potential" and is "really exciting."
He told the BBC: "What's really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing."
Ongoing Research and Future Prospects
The Cambridge team is conducting animal studies on universal seasonal flu vaccines that would not require annual adaptation, as well as an H5N1 bird flu vaccine, to prepare for a possible human pandemic from the virus currently devastating bird populations.
They are also investigating vaccines for viral hemorrhagic fevers, including Ebola species. The ongoing outbreak in the Democratic Republic of Congo involves a species for which no vaccine currently exists.
Prof Andy Pollard, director of the Oxford Vaccine Group and not involved in this study, commented that this approach is producing compelling evidence in animal research.
"It's fascinating data and people wouldn't have predicted they'd be able to generate these immune responses," he told .
He noted the true test lies in human trials, as human immune systems differ from laboratory mice due to years of exposure to infections.
More broadly, he stated artificial intelligence will be a "game changer" for vaccine research, with AI tools having the potential to predict immune system responses to vaccines, accelerating development and saving lives.
Prof Marian Knight, scientific director for the National Institute for Health and Care Research, remarked:
"The remarkable success of this AI-designed 'super-antigen' trial marks a pivotal leap forward in our ability to deliver broad, lasting viral protection."
